Peptide-based approaches to treat lupus and other autoimmune diseases

Nicolas Schall, Nicolas Page, Christophe Macri, Olivier Chaloin, Jean-Paul Briand, Sylviane Muller

Research output: Contribution to journalReview ArticleResearchpeer-review

40 Citations (Scopus)

Abstract

After a long period where the potential of therapeutic peptides was let into oblivion and even dismissed, there is a revival of interest in peptides as potential drug candidates. Novel strategies for limiting metabolism and improve their bioavailability, and alternative routes of administration have emerged. This resulted in a large number of peptide-based drugs that are now being marketed in different indications. Regarding autoimmunity, successful data have been reported in numerous mouse models of autoimmune inflammation, yet relatively few clinical trials based on synthetic peptides are currently underway. This review reports on peptides that show much promises in appropriate mouse models of autoimmunity and describes in more detail clinical trials based on peptides for treating autoimmune patients. A particular emphasis is given to the 21-mer peptide P140/Lupuzor that has completed successfully phase I, phase IIa and phase IIb clinical trials for systemic lupus erythematosus.

Original languageEnglish
Pages (from-to)143-153
Number of pages11
JournalJournal of Autoimmunity
Volume39
Issue number3
DOIs
Publication statusPublished - Sep 2012
Externally publishedYes

Keywords

  • Altered peptide ligand
  • Excipient
  • P140 peptide
  • Systemic lupus erythematosus
  • Therapeutic peptides

Cite this